T lymphocyte activation and proliferation

T lymphocyte activation and proliferation refers to a fundamental immunological process in which naïve T cells recognize antigens presented by antigen-presenting cells via their T cell receptors (TCRs), receive co-stimulatory signals (such as through CD28), and subsequently undergo clonal expansion. This results in rapid multiplication of antigen-specific effector and memory T cells capable of mounting an immune response[1][2][4]. The process is tightly regulated by metabolic reprogramming—shifting toward aerobic glycolysis—and involves complex intracellular signaling cascades that drive gene transcription necessary for cytokine production and cellular division[1][5]. Activation-induced proliferation is essential for adaptive immunity against pathogens but can also play roles in cancer surveillance, autoimmunity, infection control, and inflammation[1][5]. Therapeutic strategies often aim at enhancing or suppressing this pathway by targeting key molecules involved in these steps rather than the overall biological event itself[4]. Note: "T lymphocyte activation/proliferation" describes a **cellular function/process**, not a discrete molecule/receptor. It cannot be considered a canonical therapeutic target like an enzyme or receptor. For structured data purposes it should be flagged as incorrect if used as a molecular target entry. Drugs act upon individual proteins within this pathway—such as CD3 (targeted by OKT3/muromonab-CD3), IL2 receptor alpha/CD25 (targeted by basiliximab/daclizumab), CTLA4/CD80/86 axis (targeted by abatacept/ipilimumab)—not upon "activation/proliferation" per se[2][6].

Other names

T cell activationT cell proliferationlymphocyte activationlymphocyte proliferation